Congratulations to Brad, who joined the Department of Cancer Biology at Dana-Farber as Chair on July 1, 2021.
The Department of Cancer Biology performs lab-based research investigating the molecular pathways driving cancer. Under his leadership our 24 independent faculty and more than 300 laboratory personnel combine structural, chemical, genetic, computational, and biochemical approaches to identify molecular vulnerabilities unique to cancer cells, and to generate novel compounds with therapeutic potential.
This department has contributed directly and indirectly to a new generation of smart drugs such as imatinib (Gleevec) and gefitinib (Iressa) — bringing the promise of precision medicine closer to reality.
He is continuing the tradition of excellence in basic research promoted by our previous Chairs, Tom Roberts, PhD, Chuck Stiles, PhD, and Rosalind Segal, MD, PhD.